MPS ANTIBODY DISCOVERY

The industry leader in discovering monoclonal antibodies against multipass membrane proteins 

MAbs against GPCRs , Ion Channels and Transporters​

>95% success

20+ years expertise focused on membrane proteins

Our Technology   |    Applications   |      The MPS Advantage    |   Case Studies   |   Publications  |   FAQs

MPS Antibody Discovery: Providing Access to ‘Undruggable’ Targets

Monoclonal antibodies against membrane protein targets are notoriously difficult to isolate. MPS is the only antibody discovery platform specifically built for multipass membrane protein targets including GPCRs, ion channels and transporters.

Our technologies enable robust immune responses against conserved proteins and harness deep screening technologies, such as phage display, to discover rare and functional antibodies. 

“Access to Integral Molecular’s capabilities complements our ability to advance our therapeutic pipeline, which is dedicated to delivering novel antibody therapeutics to patients.”

-CECILE GEUIJEN, PhD, SVP & CHIEF SCIENTIFIC OFFICER OF ONCOLOGY RESEARCH, MERUS

Our Process: Proprietary Methods to Deliver Lead Candidates

The MPS platform   features advanced immunization protocols and a mix of specialized and patented technologies tailored for membrane proteins.  Patented technologies include Lipoparticles, hCAT one-step humanization and our bi-specific enabling common light chain.

Deliverables: What MPS Services Routinely Provide to Our Partners

Large panels of antibodies with diverse epitopes obtained through deep screening​

Picomolar affinity antibodies routinely isolated after phage panning​
Functional antibodies with rare qualities such as agonist and state-specific activity
Maximally human/humanized MAbs obtained through hCAT one-step humanization of chicken antibodies or ATX-Gx mice​

Validated and highly characterized preclinical-ready antibodies​

“We have been impressed by Integral Molecular’s membrane protein expertise and their proven record in discovering antibodies against membrane proteins.”

-HIDEAKI TADA, EXECUTIVE DIRECTOR, CENTER OF ONCOLOGY RESEARCH, ONO PHARMACEUTICAL CO., LTD.

MPS Success Stories: Trusted by Our Partners​

website-logos-200x200-944-×-236-px.png

Featured Case Studies

Publications Featuring the MPS Antibody Discovery Platform

Frequently Asked Questions

Ready To Get Started?

We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.

Or call (215) 966-6061